Moreover, growing evidence indicates that alteration of other major homologous recombination repair (HRR) proteins, such as ATM, may induce a response to PARP inhibitors in patients affected by multiple solid malignancies, such as prostate cancer and triple-negative breast cancer [94,95]. The gene discussed is ATM; the disease is triple-negative breast carcinoma.